Diabetic Nephropathies Clinical Trial
Official title:
Effect of SGLT2 Inhibitor on Proteinuria in Diabetic Patients
Diabetes Mellitus is the leading cause of end stage renal disease. As proven by many studies , controlling proteinuria can delay the progression to end stage renal disease.This work will study the effect of sodium glucose co transporter 2 inhibitor , a new antihyperglycemic drug , on proteinuria and to compare its effect with the effect of classic antiproteinuric drugs as angiotensin converting enzyme inhibitor , aspirin and statins.
Diabetic nephropathy involves progressive stages including glomerular hyperfilteration ,
microalbuminuria , overt proteinuria and a decline in glomerular filteration rate leading to
end stage renal disease.
Despite all the available interventions available for diabetic patients including tight
glycemic control , and blood pressure control , using angiotensin converting enzyme
inhibitors, angiotensin II receptor antagonist renal disease remains prevalent and progress
in these patients.
The newer therapy of diabetes is the use of sodium glucose cotransporter 2 inhibitor as it
has the potential of renoprotection in patients with diabetic nephropathy just as ACEI and
ARBS to reduce glomerular hyperfilteration .This action may reduce albuminuria.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05530356 -
Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study
|
||
Terminated |
NCT01575379 -
A Pilot Study of Allopurinol to Prevent Kidney Function Loss in Type 1 Diabetes
|
Phase 4 | |
Active, not recruiting |
NCT05656963 -
The Influencing Factors and Mechanism of High Incidence of Thrombotic Events in Patients With MN and DKD
|
||
Not yet recruiting |
NCT04084886 -
TCF7L2 Gene Polymorphism and AGEs in Diabetic Nephropathy
|
||
Active, not recruiting |
NCT04869761 -
Stem Cell Therapy for Chronic Kidney Disease
|
Phase 1 | |
Recruiting |
NCT04570735 -
MRI Biomarkers in Diabetic Kidney Disease
|
||
Completed |
NCT03165240 -
This International Study Tests BI 690517 in Patients With Diabetic Kidney Disease. The Study Tests How 3 Different Doses of BI 690517 Are Taken up in the Body and How Well They Are Tolerated
|
Phase 1 | |
Completed |
NCT01968668 -
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Japanese Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy (ARTS-DN Japan)
|
Phase 2 | |
Completed |
NCT02552277 -
A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy
|
Phase 2 | |
Terminated |
NCT03840343 -
Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease
|
Phase 1 | |
Terminated |
NCT02410005 -
Intervention Using Vitamin D for Elevated Urinary Albumin Treated With Losartan in Diabetes (IDEAL)
|
Phase 2/Phase 3 | |
Unknown status |
NCT01918488 -
Increased Activity of a Renal Salt Transporter (ENaC) in Diabetic Kidney Disease
|
N/A | |
Completed |
NCT00915200 -
N-Acetylcysteine and Milk Thistle for Treatment of Diabetic Nephropathy
|
Phase 2 | |
Completed |
NCT03165227 -
This Study Tests a New Medicine Called BI 685509 in Patients That Have Kidney Problems Because of Diabetes. The Study Tests How BI 685509 is Taken up in the Body and How Well it is Tolerated (Multiple Rising Doses)
|
Phase 1 | |
Active, not recruiting |
NCT04531163 -
Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03620773 -
Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes
|
Phase 1/Phase 2 | |
Completed |
NCT03618420 -
Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03284996 -
Doppler Ultrasound in Early Detection of Diabetic Nephropathy Type 2 Diabetes Mellitus.
|
N/A | |
Completed |
NCT03334318 -
PERL Continuous Glucose Monitoring (CGM) Study
|
||
Completed |
NCT04380584 -
Relation Between Plasma Apelin Level and Diabetic Nephropathy in Type 2 Diabetes Patients.
|